Adrenomyeloneuropathy (AMN) is a disorder due to a disturbance in the peroxisomal b-oxidation of saturated very long chain fatty acids. It is characterized by symptoms of the nervous as well as the endocrine systems, especially the adrenal cortex and the gonads. We investigated the testicular function in 49 male AMN patients aged 36.2 Ϯ 1.5 years (range, 18.5-59 years). Twenty-four of these patients were suffering from adrenocortical insufficiency. Twenty-five AMN patients showed neurological symptoms without ' Addison's disease'. To register the frequency and the degree of gonadal impairment, LH and FSH, testosterone, free testosterone and inhibin-B were determined. Gonadotropin concentrations were significantly higher in AMN patients than in healthy controls (LH, 8.0 Ϯ 1.2 vs 2.77 Ϯ 0.11 IU/l; FSH, 10.1 Ϯ 1.6 vs 4.0 Ϯ 0.17 IU/l; P < 0.001). Serum LH was elevated in 31 patients (63.3%); 28 patients (57.1%) showed elevated serum FSH indicating deficient spermatogenesis. Mean testosterone did not differ significantly between patients and healthy controls, but mean free testosterone was significantly lower in patients than in controls (16.3 Ϯ 1.0 vs 28.5 Ϯ 1.68 pg/ml, P < 0.002). Inhibin-B concentrations did not differ between AMN patients and healthy men. The testosterone/LH ratio reflecting an impairment of the Leydig cells was significantly lower in AMN patients than in controls (P < 0.01). An impairment of the Leydig cells and/or of the Sertoli cells was evident in 81.6% of AMN patients. Twenty-one of thirty-nine patients (53.8%) admitted erectile dysfunction.
Introduction
Adrenoleukodystropy (ALD), as well as the more benign clinical variant of adult adrenomyeloneuropathy (AMN), is an inherited disturbance in the peroxisomal degradation of saturated very long chain fatty acids (VLCFA) leading to an accumulation of VLCFA in various tissues (1) . This accumulation of VLCFA damages the central and peripheral myelin, the adrenal cortex as well as the testes (2). There is a high variability in the phenotypic expression of ALD/AMN (3) . Patients may present central and peripheral nerve disease, adrenocortical insufficiency or testicular impairment. In most adult patients with ALD, referred to as AMN, the neurologic pathology involves the long ascending and descending tracts of the spinal cord and the peripheral nervous system (4) . Various degrees of an additional brain involvement are observed in about 45% of the AMN patients, better referred to as adreno-leuko-myelo-neuropathy (5) . Delineation of brain abnormalities is valuable for differentiation of adult ALD phenotypes and for prognostic and therapeutic considerations (6) (7) (8) . Moser et al. (3) reported that 60% of ALD/AMN patients with neurologic deficits suffer from adrenocortical insufficiency. Recently, we reported on the primary occurrence of adrenocortical insufficiency in AMN before the onset of neurological symptoms (9) . Since sensitive VLCFA assays have been introduced (10, 11) , the diagnosis of subclinical types of ALD/AMN, e.g. ' Addison's only' phenotype and heterozygotes, as well as of the clinical subtypes can be assured. No conclusive data are available concerning the frequency of testicular impairment in patients with neurological symptoms. Therefore, we investigated the endocrine testicular function in 49 adult patients with AMN. Serum luteinizing hormone (LH) and testosterone were used for the description of the endocrine function of the Leydig cells; serum follicle-stimulating hormone (FSH) was used to describe the function of the Sertoli cells reflecting spermatogenesis (12) . Inhibin-B -a heterodimeric glycoprotein hormone primarily from gonadal source in the male's circulation (13) -may be involved in the negative feedback regulation of FSH and may offer a useful serum marker describing gonadal functions in AMN. Additionally, the testosterone/LH ratio, which is considered to be a sensitive parameter for the function of the Leydig cells (14) , was used to detect less impairment of these cell functions, especially in the individual AMN patient.
Subjects and methods

Patients
We studied 49 adult patients with AMN (age: 36.0 Ϯ 1.5 (mean Ϯ S.E.M.) years; range, 18.5-59 years); 105 healthy men (age: 33.9 Ϯ 1.19 years; range, 18-63 years) served as controls. During a follow-up, patients underwent a complete history (detailing symptoms of adrenocortical insufficiency and neurological disturbances), physical examinations and endocrine studies. In all patients the diagnosis was verified by the evaluation of their medical charts, and the elevation of saturated plasma VLCFA concentrations. The spinal cord and peripheral nerves were affected in 48 of these 49 AMN patients with various degrees of spastic paraparesis, sensory disturbances in the legs and, to a lesser extent, impairment of bladder function as well as sexual disturbances. One patient showed adrenocortical insufficiency with a serum cortisol of 0.32 mmol/l but no increase in cortisol (0.29 mmol/l) after 250 mg Synacthen but, to date, no neurological impairment could be observed in this patient. Besides neurological deficits, 23 AMN patients had adrenocortical insufficiency, which was treated with hydrocortisone. Symptoms of adrenocortical insufficiency occurred at the age of 17.4 Ϯ 2.0 years (range, 5.0-41.0 years) and symptoms of neurological disturbance around the age of 28.0 Ϯ 1.6 years (range, 9.0-57.0 years). The interval between the onset of adrenocortical insufficiency and neurological impairment was 7.93 Ϯ 1.32 years (range, 0.5-18 years). In each case adrenocortical insufficiency occurred first (9) . Twenty-five AMN patients showed neurological impairment without clinically manifest adrenocortical insufficiency; 21 of these 25 patients had a normal response to Synacthen with an increase in serum cortisol from 0.43 Ϯ 0.04 to 0.72 Ϯ 0.04 mmol/l, the remaining 4 patients had serum cortisol above 0.5 mmol/l (range, 0.51-0.66 mmol/l), thus ruling out ' Addison's disease'. Sexual history -detailing symptoms of erectile dysfunction -was available in 39 of the 49 AMN patients. This investigation was passed by the Ethics Committee of the University of Bonn.
Endocrine studies
Testicular function studies were performed during follow-up hospitalization. Blood was drawn in the morning for routine biochemical studies, serum was separated and stored at ¹20ЊC until assay. LH, FSH, testosterone and free testosterone were determined by IRMA (LH, FSH: Serono, Freiburg, Germany) and RIA (testosterone, free testosterone: DPC, Biermann, Bad Nauheim, Germany). Reference values of gonadotropins, testosterone and the testosterone/LH ratio were established indicating the 5th to 95th percentile of 105 age-matched healthy male volunteers: the reference values for LH are 1.2-4.6 IU/l, for FSH 1.7-7.8 IU/l, for testosterone 11.5-27.3 nmol/l, for the testosterone/LH ratio 3.3-17.9 nmol/IU and for free testosterone 48.9-165 pmol/l (n = 44). The within-assay variation for LH (concentration: 2.1 IU/l), FSH (5.5 IU/l), testosterone (12.5 nmol/l) and free testosterone (67.3 pmol/l) was 3.5%, 3.9%, 9.5% and 4.0% respectively (n = 20); the between-assay variation was 9.4%, 5.3%, 9.8% and 3.7% respectively (n = 18).
Inhibin-B was determined by a two-site enzymelinked immunosorbent assay (ELISA) using microtiter plates coated with a specific monoclonal capture antibody to the inhibin-B b-subunit and a mouse monoclonal antibody to the N-terminal portion of the 20 kDa a-subunit of inhibin, which was conjugated to alkaline phosphatase for detection. A cross-reaction of less than 0.1% in the inhibin-B ELISA was described for activin A, activin B, and purified human pro-aC, whereas the cross-reaction of inhibin-A was 0.5% (12) . Sensitivity of the assay was 5 pg/ml; the within-assay variation was 8% (210 pg/ml) and the between-assay variation was less than 10%.
Adrenal function tests were performed in the morning. Serum cortisol was determined by fluorescence polarization immunometric assay (FPIA, TDx, Abbott, Wiesbaden, Germany) before and 30 min after i.v. administration of 250 mg synthetic ACTH(1-24) (Synacthen, Ciba-Geigy, Wehr, Germany). The normal range of early morning serum cortisol was 0.22-069 mmol/l; the within-and between-assay coefficients of variation were 3.4% and 2.2% respectively with a concentration of 0.34 mmol/l (n = 10). Thirty minutes after Synacthen, an increase in serum cortisol of more than 0.17 mmol/l was considered to be normal.
Statistical analyses
Data were presented as means Ϯ S.E.M. and ranges as well as the 5th and 95th percentiles to establish reference values. Statistical analyses were performed using the Mann-Whitney U test and the Spearman's range correlation (r). A P value lower than 0.05 was considered to be significant.
Results
Mean gonadotropin concentrations were significantly higher in AMN patients than in healthy controls (P < 0.001). Thirty-one patients (63.3%) had elevated serum LH, and twenty-eight patients (57.1%) had elevated FSH concentrations. There was no significant difference in serum gonadotropin concentrations between patients with adrenocortical insufficiency and those without it (Fig. 1a,b) .
Mean testosterone concentrations did not differ significantly between the patients and healthy subjects (although 2 patients with ' Addison's disease' showed slightly subnormal testosterone concentrations), and there were no significant differences in mean testosterone observed in patients with or without adrenocortical insufficiency (Fig. 1c) . Mean free testosterone concentrations were within the normal range, but AMN patients showed significantly lower free testosterone than controls (P < 0.002). Fourteen patients (33.3%) had subnormal free serum testosterone. No significant differences in mean free testosterone concentrations were observed between the two subgroups of patients (Fig. 1d) .
Mean inhibin-B did not differ significantly between AMN patients (210 Ϯ 13.1 pg/ml, n = 33) and healthy male controls (213 Ϯ 13.0 pg/ml, n = 40; Fig. 2 ), but AMN patients had significantly higher serum FSH than healthy controls (P < 0.02). No significant correlation between serum FSH and inhibin-B was observed in AMN patients (r = ¹0.196; P = 0.137) whereas in healthy controls a weak inverse correlation was evident (r = ¹0.346, P < 0.02).
The mean testosterone/LH ratio was significantly lower in the patient group compared with healthy controls (P<0.01; Fig. 3) ; patients with adrenocortical insufficiency had a significantly lower testosterone/LH ratio than those with neurological impairment but regular adrenocortical function (P < 0.05). Twenty-four AMN patients (48.9%) showed a lower testosterone/LH ratio compared with controls: 3 patients (6.1%) had a low testosterone/LH ratio only, while 15 patients (30.6%) showed both a low testosterone/LH ratio and supranormal serum LH and FSH. A selective elevation of serum LH with a normal testosterone/LH ratio could be observed in 6 AMN patients (12.2%); 5 patients (10.2%) showed a selective elevation of serum FSH. Another subset of 5 patients (10.2%) had elevated LH concentrations and a low testosterone/LH ratio. Elevated serum LH and FSH with a normal testosterone/LH ratio could be observed in 7 patients (14.3%). Thus, an impairment of the testicular function was evident in 40 of 49 AMN patients (81.6%) reflected by a low testosterone/LH ratio in 24 patients, a selective elevation of LH in 4 and of FSH in 5 patients as well as by an elevation of both gonadotropins in 7 patients. Normal gonadotropin concentrations and a normal testosterone/ LH ratio reflecting regular testicular functions were only present in 9 AMN patients (18.4%; 4 patients with and 5 without adrenocortical insufficiency).
Twenty-one of the thirty-nine AMN patients (53.8%) suffered from sexual impotence; eighteen patients (46.2%) reported normal sexual functioning. Patients with erectile dysfunction were significantly older than those with no anamnestic dysfunction (P < 0.01). Clinical data and the endocrine function of these 39 patients are presented in Table 1 .
Discussion
In the present investigation, we demonstrated that about 63% of the AMN patients studied had elevated serum LH, indicating an impairment of the Leydig cells, and about 57% had elevated serum FSH, reflecting deficient spermatogenesis. Our results are in contrast to data reported by Moser et al. (15) who showed elevated levels of LH and FSH in 42% and 30% respectively of their patients. The reasons for these discrepancies remain unclear, since Moser and coworkers showed no individual hormone data for their patients and did not give precise reference values of their hormone assays. In our patients, mean free testosterone concentrations were significantly lower compared with controls, which may have been due to a higher protein binding of testosterone in AMN patients. The testosterone/LH ratio -a sensitive marker of the Leydig cell function (14) -was significantly lower in AMN patients: 24 AMN patients had a subnormal testosterone/LH ratio; 3 of these patients showed only a low testosterone/LH ratio but normal gonadotropins and testosterone. Therefore, especially in the individual patient, the testosterone/LH ratio is more sensitive than either LH or testosterone alone for detecting an impairment of the Leydig cell function, which may be compensated for and subclinical. As Leydig cells are damaged, endogenous LH is not able to stimulate testosterone synthesis and/or secretion to the same degree as in healthy subjects. A selective elevation of serum LH or FSH could be observed in 9 patients; 7 patients had an elevation of both gonadotropins. Thus, an impairment of the Leydig cell function and/or an impairment of spermatogenesis, could be observed in more than 80% of AMN patients. Our results are in contrast to the findings of Libber et al. (16) , who only found a minor testicular deficiency in ALD/AMN patients with clinical adrenocortical insufficiency and with neurological symptoms; however, the number of patients was limited and the majority of patients were pubertal boys suffering from ALD. Our findings confirm that disturbances of testosterone synthesis/secretion, which are still subclinical in a compensated form, are based on a primary testicular defect in AMN. Regarding elevated gonadotropins and normal testosterone concentrations, a defect of the hypothalamo-pituitarygonadal axis could almost be excluded in AMN. The finding of a primary testicular defect is in accordance with data reported by Powers & Schaumburg (2, 17). They described testicular lesions at an ultra-structural level consisting of lamellae and lamellar-lipid profiles in mature, immature or precursor Leydig cells. A decrease in the number of Leydig cells, a vacuolation of the Sertoli cells' endoplasmatic reticulum as well as of the germ cells was observed in ALD/AMN (18) .
Inhibin, a heterodimeric glycoprotein hormone of primary gonadal origin, may possibly be an important regulator of pituitary FSH release (19) . An inverse correlation was found between FSH and inhibin-B -the predominant form of circulating inhibin in the male -in healthy semen donors as well as in infertile patients with elevated serum FSH (20) . In our study, inhibin-B did not differ significantly between AMN patients and healthy men. In contrast to Illingworth et al. (20) , we observed a weak inverse correlation between serum FSH and inhibin-B in healthy men, which may be due to the higher number of subjects in our trial. Although serum FSH was significantly higher in AMN patients, no significant correlation was observed between FSH and inhibin-B in AMN. As shown by Tsatsoulis et al. (21) in patients treated for germ cell cancer, cytotoxic damage to the testis led to reduced serum inhibin concentrations. In contrast to these tumor patients, a severe disturbance of the functions of Sertoli cells could almost be excluded in AMN, whereas the influence of less damage to the Sertoli cells or less disturbance of spermatogenesis on circulating inhibin-B are unknown and must be a matter of further investigation.
About 54% of AMN patients suffered from erectile dysfunction. These patients showed adrenocortical insufficiency, an impairment of the endocrine functions reflected by a subnormal testosterone/LH ratio and disturbances of the bladder function, reflecting a neurologic involvement of the urogenital tract in this disease, more frequently than patients reporting normal sexual functions. AMN patients suffering from impotence, which is probably a manifestation of neurological disease due to spinal cord involvement (4), seem to have a more severe manifestation of their disease, but we were not able to make a valid comparison as patients with erectile dysfunction were significantly older than those reporting normal sexual life. After exclusion of vascular and psychogenic disturbances, these patients are referred to vacuum methods (22) or intracavernous self-injection of vasoactive substances (23) , which may benefit their sexual life.
In conclusion, an impairment of sexual functions was suffered by 53.8% of AMN patients. Immunoreactive inhibin-B does not appear to offer an additional marker of Sertoli cell function in AMN. The majority of AMN patients (81.6%) showed testicular dysfunctions reflected by a subnormal testosterone/LH ratio and/or elevated gonadotropins. These findings confirm the term 'adreno-testiculo-myelo-neuropathy' (2). 
